A

· Aarskog, D. Association between maternal intake of diazepam and oral clefts (letter). Lancet. 1975 ; 2 : 921.

· Adedoyin, A., Arns, P.A., Richards, W.O. et al. Selective effect of liver disease on the activities of specific metabolizing enzymes : Investigation of cytochromes P450 2C19 and 2D6. Clin. Pharmacol. Ther. 1998 ; 64 : 8-17.

· Agundez, J.A.G., Ledesma, M.C., Ladero, J.M. et al. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin. Pharmacol. Ther. 1995 ; 57 : 265-269.

· Alderman, J., Preskorn, S.H., Greenblatt, D.J. et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J. Clin. Psychopharmacol. 1997 ; 17 : 284-291.

· Altshuler, L.L. & Hendrick, V.C. Pregnancy and psychotropic medication : changes in blood levels. J. Clin. Psychopharmacol. 1996 ; 16 : 78-80.

· Altshuler, L.L., Cohen, L., Szuba, M.P. et al. Pharmacologic management of psychiatric illness during pregnancy : dilemmas and guidelines. Am. J. Psychiatry. 1996 ; 153 : 592-606.

· American Academy of Neurology. Assessment : generic substitution for antiepileptic medication. Neurology. 1990 ; 40 : 1641-1643.

Principio de página

B

· Bachrach, LL. Asylum and chronically ill psychiatric patients. Am. J. Psychiatry. 1984; 141.

· Baldessarini, R.J. Drugs and the treatment of psychiatric disorders. In Goodman & Gilman. The pharmacological basis of therapeutic. 9th edn. Ed. G & G N.Y. 1996.

· Ball, S., Ahern, D., Kao, J. et al. Venlafaxine (VF) : effects on CYP2D6 dependent imipramine (IMP) and desipramine (DMI) 2-hydroxylation : comparative studies with fluoxetine (FLU) and effects on CYP1A2, CYP3A4 and CYP2C9 (abstract). Clin. Pharmacol. Ther. 1996 ; 59 : 170.

· Banister, P., Dafoe, C., Smith, E.S.O. et al. Possible teratogenicity of tricyclic antidepressants (letter). Lancet. 1972 ; 1 : 838-839.

· Barbhaiya, R.H., Shukla, U.A., Kroboth, P.D. et al. Coadministration of nefazodone and benzodiazepines, II : a pharmacokinetic interaction study with triazolam. J. Clin. Psychopharmacol. 1995 ; 15 : 320-326.

· Belknap, S.M. & Nelson, J.E. Drug interactions in psychiatry. In Musa, M.N. Pharmacokinetics and therapeutic monitoring of psychiatric drugs. Thomas Books. Springfield, 1993.

· Bertele, V. & Garattini, S. Evaluación de la eficacia de los fármacos. Investigación y ciencia (Sci. Am.). 1997 : 78-88.

· Bertilsson, L., Lou, Y.Q., Du, Y.L. et al. Pronounced differences between native Chineses and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin. Pharmacol. Ther. 1992 ; 51 : 388-397.

· Bertilsson, L. & Kalow, W. Why are diazepam metabolism and polimorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations, but not in Chinese populations ? Clin. Pharmacol. Ther. 1993 ; 53 : 608-610.

· Bertilsson, L. & Dahl, M-L. Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs. 1996 ; 5 : 200-223.

· Bloch, R.G., Dornseif, A.S., Buchberg, A.S. et al. The clinical effect of isoniazid and iproniazid in the treatment of pulmonary tuberculosis. Ann. Intern. Med. 1954 ; 40 : 881-900.

· Brosen, K. & Gram, L.F. First-pass metabolism of imipramine and desipramine : impact of the sparteine oxidation phenotype. Clin. Pharmacol. Ther. 1988 ; 43 : 400-406.

· Brownell, K.D. The double-blind in danger : untoward consequences of informed consent. Am. J. Psychiatry. 1982 ; 139 : 1487-1489.

· Burgeois, B.F.D. Important pharmacokinetic properties of antiepileptic drugs. Epilepsia. 1995 ; 36 (suppl. 5) : S1-S7.

· Burrows, G.D., Scoggins, B.A., Turecek, L.R. et al. Plasma nortriptyline and clinical response. Clin. Pharmacol. Ther. 1974 ; 16 : 639-644.

Principio de página

C

· Cabrera, F.M. & Battaglia, G. Delayed decreases in brain 5-HT2a and 2c receptor density and function in male rat progeny following prenatal fluoxetine. J. Pharmacol. Exp. Ther. 1994 ; 269 : 637-645.

· Chamberlain, S., Hahn, P.M., Cassan, P. & Reid, R.L. Effect of menstrual cycle phase and oral contraceptive use on serum lithium levels after a loading dose of lithium in normal women. Am. J. Psychiatry. 1990 ; 147 : 907-909.

· Chouinard, G., Jones, B.D., Annable, L. & Ross-Chouinard, A. Sex differences and tardive dyskinesia (letter). Am. J. Psychiatry. 1980 ; 137 : 507.

· Ciraulo, D.A., Shader, R.I., Greenblatt, D.J. & Creelman, W.L. Drug interactions in psychiatry. W & W. Baltimore, 1995.

· Cohen, L.S., Friedman, J.M., Jefferson, J.W. et al. A revaluation of risk of in utero exposure to lithium. JAMA. 1994; 271 : 146-150.

· Cowe, L., Lloyd, D.J. & Dawling, S. Neonatal convulsions caused by withdrawal from maternal clomipramine. Br. Med. J. 1982 ; 284 : 1837-1838.

· Crewe, H.K., Lennard, M.S., Tucker, G.T. et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br. J. Clin. Pharmacol. 1992 ; 34 : 262-265.

Principio de página

D

· Dahl, M-L., Johansson, I., Porsmyr Palmertz, M. et al. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin. Pharmacol. Ther. 1992 ; 51 : 12-17.

· Dansky, L., Rosenblatt, D. & Andermann, E. Mechanisms of teratogenesis : folic acid and antiepileptic therapy. Neurology. 1992 ; 42 (suppl. 5) : 32-42.

· Davis, C., Ralevski, E., Kennedy, S.H. & Neizert, C. The role of personality factors in the reporting of side effect complaints to moclobemide and placebo : a study of healthy male and female volunteers. J. Clin. Psychopharmacol. 1995 ; 15 : 347-352.

· de Abajo, F.J. & Gracia, D.M. Ética del uso de placebo en investigación clínica. Investigación y ciencia (Sci. Am.). 1997 : 90-99.

· DeVane, C.L. Pharmacogenetics and drug metabolism of newer antidepressant drugs. J. Clin. Psychiatry. 1994 ; 55 (suppl.) : 38-47.

· DiMasi, J.A., Seibring, M.A. & Lasagna, L. New drug development in the United States, 1963 to 1992. Clin. Pharmacol. Ther. 1994 ; 55 : 609-622.

· DiMasi, J.A. & Lasagna, L. The economics of psychotropic drug development. In Bloom, F.E. & Kupfer, D.J. Psychopharmacology : the fourth generation of progress. Raven Press. New York, 1995.

Principio de página

E-F

· Eggermont, E. Withdrawal symptoms in neonates associated with maternal imipramine therapy. Lancet. 1973 ; 2 : 680.

· Ellinwood, E.H., Easier, M.E., Linnoila, M. et al. Effects of oral contraceptives and diazepam-induced psychomotor impairment. Clin. Pharmacol. Ther. 1983 ; 35 : 360-366.

· Ereshefsky, L., Jann, M.W., Saklad, S.R. et al. Bioavailability of psychotropic drugs : historical perspective and pharmacokinetic overview. J. Clin. Psychiatry. 1986 ; 47 : 6-15.

· Ereshefsky, L. Drug-drug interactions involving antidepressants : focus on venlafaxine. J. Clin. Psychopharmacol. 1996a ; 16 (suppl. 2) : 37S-53S.

· Fawcett, J. Compliance : definitions and key issues. J. Clin. Psychiatry. 1995 ; 56 (suppl. 1) : 4-8.

· Forrest, F.M. et al. Modification of chlorpromazine metabolism by some other drugs frequently administered to psychiatric patients. Biol. Psychiatry. 1970 ; 2 : 53.

Principio de página

G

· Gaily, E. & Granstrom, M.L. Minor anomalies in children of mother with epilepsy. Neurology. 1992 ; 42 (suppl. 5) : 128-131.

· Geller, B., Cooper, T.B., Graham, D.L. et al. Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-years-olds with major depressive disorder. J. Am. Acad. Child. Adolesc. Psychiatry. 1992 ; 31 : 34-44.

· Gerner, R.H. Psychiatric effects of nonpsychiatric medications. In Dunner, D.L. Current Psychiatric theraphy. W.B. Saunders Company. Philadelphia, 1993.

· Guerrero,R., González, C.L. & Medina, E. Epidemiología. Fondo Educativo Interamericano. Bogotá. 1981.

· Goff, D.C. & Baldessarini, R.J. Drug interactions with antipsychotic agents. J. Clin. Psychopharmacol. 1993 ; 13 : 57-67.

· González, F.J. & Meyer, U.A. Molecular genetics of the debrisoquine/sparteine polymorphism. Clin. Pharmacol. Ther. 1991 ; 50 : 233-238.

· Goodman & Gilman. The pharmacological basis of therapeutics. 9th edn. Ed. McGraw-Hill N.Y. 1996.

· Goss, J.E., Ramo, B.W. & Blake, K. Torsades de pointes associated with astemizole (Hismanal) therapy (letter). Arch. Intern. Med. 1993 ; 153 : 2705.

· Grebb, J.A. General Principles of Psychopharmacology. In Kaplan, H.I. & Sadock, B. Comprehensive Textbook of Psychiatry. 6th edn. W & W. Baltimore, 1995.

· Greenblatt, D.J., Koch-Weser, J. Intramuscular injection of drugs. N. Engl. J. Med. 1976 ; 295 ; 542-546.

· Greenblatt, D.J., Allen, M.D., Harmatz, J.S. & Shader R.I. Diazepam disposition determinants. Clin. Pharmacol. Ther. 1980a ; 27 : 301-312.

· Greenblatt, D.J., Divoll, M., Harmatz, J.S. & Shader, R.I. Oxazepam kinetics: effects of age and sex. J. Pharmacol. Exp. Ther. 1980b ; 215 : 86-91.

· Greenblatt, D.J., Friedman, H., Burstein, E.S. et al. Trazodone kinetics: effect of age, gender and obesity. Clin. Pharmacol. Ther. 1987 ; 42 : 193-200.

· Greenblatt, D.J., von Moltke, L.L. & Shader, R.I. The importance of presystemic extraction in clinical psychopharmacology (editorial). J. Clin. Psychopharmacol. 1996 ; 16 : 417-419.

· Greene, D.S., Salazar, D.E., Dockens, R.C. et al. Coadministration of nefazodone and benzodiazepines, III : a pharmacokinetic interaction study with alprazolam. J. Clin. Psychopharmacol. 1995 ; 15 : 399-408.

· Guze, B.H. & Baxter, L.R. The serotonin syndrome : case responsive to propranolol. J. Clin. Psychopharmacol. 1986 ; 6 : 119-120.

Principio de página

H-I

· Hanlon, L., Romaine, M., Gilroy, F. et al. Lithium chloride as a substitute for sodium chloride in the diet. JAMA. 1949 ; 139 : 688-692.

· Honig, P.K., Wortham, D.C., Zamani, K. et al. Terfenadine-ketoconazole interaction : pharmacokinetic and electrocardiographic consequences. JAMA. 1993 ; 269 : 1513-1518.

· Hukkinen, S.K., Varhe, A., Olkkola, K.T. et al. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin. Pharmacol. Ther. 1995 ; 58 : 127-131.

· Hurwitz, N. Predisposing factors in adverse reactions to drugs. Br. Med. J. 1969 ; 1 : 536-539.

· Idanpaan-Heikkila, J. & Saxen, L. Possible teratogenicity of imipramine-chloropyramine. Lancet. 1973 ; 2 : 282-284.

Principio de página

J-K

· Jacobson, S.J., Jones, K., Johnson, K. et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet. 1992 ; 339 : 530-533.

· Janowsky, D., El-Yousef, M., Davis, J. & Sekerke, H. A cholinergic-adrenergic hypothesis of mania and depression. Lancet. 1972 ; 2 : 632-635.

· Jason, K.M., Cooper, T.B. & Friedman, E. Prenatal exposure to imipramine alters early behavioral development and beta adrenergic receptors in rats. J. Pharmacol. Exp. Ther. 1981 ; 217 : 461-466.

· Jeavons, P.M. Sodium valproate and neural tube defects. Lancet. 1982 ; 2 : 1282-1283.

· Jefferson, J.W. & Greist, J.H. Lithium. In Kaplan, H.I. & Sadock, B. Comprehensive Textbook of Psychiatry. 6th edn. W & W. Baltimore, 1995.

· Johansson, I., Lundqvist, E., Bertilsson, L. et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D-locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA. 1993 ; 90 : 11825-11829.

· Kaplan, E.M. Antidepressant noncompliance as a factor in the discontinuation syndrome. J. Clin. Psychiatry. 1997 ; 58 (suppl. 7) : 31-36.

· Kappas, A., Anderson, K.E., Connery, A.H. et al. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clin. Pharmacol. Ther. 1976 ; 20 : 643-653.

· Kenakin, T. The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol. Rev. 1996 ; 48 : 413-457.

· Klaiber, E.L., Broverman, D.M., Vogel, W. & Kobayashi, Y. Estrogen therapy for severe persistent depressions in women. Arch. Gen. Psychiatry. 1979 ; 36 : 550-554.

· Klaasen, C.D. Casarett & Doull's toxicology. The basic science of poisons. 5th edn. McGraw-Hill. N.Y. 1996.

· Kuenssberg, E.V. & Knox, J.D. Imipramine in pregnancy. Br. Med. J. 1972 ; 2 : 292.

· Kuhn, R. The treatment of depressive states with G-22355 (imipramine hydrochloride). Am. J. Psychiatry. 1958 ; 115 : 459-464.

· Kupferschmidt, H.H.T., Ha, H.R., Zieglar, W.H. et al. Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther. 1995 ; 58 : 20-28.

Principio de página

L

· Lam, Y.W.F., Casto, D.T. & Dunn, J.F. Drug metabolizing capacity in Mexican Americans (abstract). Clin. Pharmacol. Ther. 1991 ; 49 : 159.

· Lane, R.M. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. 1996 ; 11 (suppl. 5) : 31-61.

· Lemberger, L., Rowe, H., Bosomworth, J.C. et al. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin. Pharmacol. Ther. 1988 ; 43 : 412-419.

· Leon, A.C., Marzuk, P.M. & Portera, L. More reliable outcome measures can reduce sample size requeriments. Arch. Gen. Psychiatry. 1995 ; 52 : 867-871.

· Levy, R.H. Cytochrome P450 isosymes and antiepileptic drug interactions. Epilepsia. 1995 ; 36 (suppl. 5) : S8-S13.

· Levy, G. What are narrow therapeutic index drugs ? Clin. Pharmacol. Ther. 1988 ; 63 : 501-505.

· Licht, R.W., Gouliaev, G., Vestergaard, P & Frydenberg, M. Generalisability of results from randomised drug trials. A trial on antimanic treatment. Br. J. Psychiatry. 1997 ; 170 : 264-267.

· Lin, K.M., Poland, R.E., Lau, J.K. et al. Haloperidol and prolactin concentrations in Asians and Caucasians. J. Clin. Psychopharmacol. 1988 ; 8 : 195-201.

· Lin, K.M. & Poland, R.E. Ethnicity, culture, psychopharmacology. In Bloom, F.E. & Kupfer, D.J. Psychopharmacology : the fourth generation of progress. Raven Press. New York, 1995.

· Lin, E.H., Von Korff, M., Katon, W. et al. The role of the primary care physician in patients'adherence to antidepressant therapy. Med. Care 1995 ; 33 : 67-74.

· Llerena, A., Edman, G., Cobaleda, J. et al. Relationship between personality and debrisoquine hydroxylation capacity-suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr. Scand. 1993 ; 87 : 23-28.

Principio de página

M

· MacDonald, J.T. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology. 1987 ; 37 : 1885.

· MacLeod, S.M., Giles, H.G., Bengert, B. et al. Age and gender-related differences in diazepam pharmacokinetics. J. Clin. Pharmacol. 1979 ; 19 : 15-19.

· Masimirembwa, C., Bertilsson, L., Johansson, I. et al. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin. Pharmacol. Ther. 1995 ; 37 : 656-661.

· Melmo, K.L. Preventable drug reactions. Causes and cures. N. Engl. J. Med. 1971 ; 284 : 1361-1368.

· Meyer, F.P., Troger, U & Rohl, F-W. Adverse nondrug reactions : an update. Clin. Pharmacol. Ther. 1996 ; 60 : 347-352.

· MRC Vitamin Study Research Group. Prevention of neural tube defects : results of the Medical Research Council Vitamin Study. Lancet. 1991 ; 338 : 131-137.

Principio de página

N

· Nakamura, K., Goto, F., Ray, W.A. et al. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 1985 ; 38 : 402-408.

· Napoliello, M.J. Psychopharmacology in children : interethnic considerations. IACAPAP Bulletin. 1997 ; 5 : 8-11.

· Nelson, K. & Holmes, L.B. Malformations due to presumed spontaneous mutations in newborn infants. N. Engl. J. Med. 1989 ; 320 : 19-23.

· Nierenberg, A.A. & Cole, J.O. Antidepressant adverse drug reactions. J.Clin. Psychiatry. 1991 ; 52 (suppl.) : 40-47.

· Nuwer, M.R., Browne, T.R., Dodson, W.E. et al. Generic substitutions for antiepileptic drugs. Neurology. 1990 ; 40 : 1647-1651.

Principio de página

O-P

· Olfson, M. et al. Pharmacotherapy in outpatient psychiatric practice. Am. J. Psychiatry. 1994; 151/4.

· Olkkola, K.T., Aranko, K., Luurila, H. et al. A potentially hazardous interaction between erythromycin and midazolam. Clin. Pharmacol. Ther. 1993 ; 53 : 298-305.

· Omtzigt, J.G.C., Los, F.J., Grobbee, D.E. et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology. 1992 ; 42 (suppl. 5) : 119-125.

· Otton, S.V., Ball., S.E., Cheung, S.W. et al. Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine and other 5-HT uptake inhibitors (abstract P1-71). Clin. Pharmacol. Ther. 1994 ; 55 : 141.

· Pardridge, W.M. Recent advances in blood-barrier transport. Ann. Rev. Pharmacol. Toxicol. 1988 ; 28 : 25-39.

· Pare, C.M.B. Thre present status of monoamine oxidase inhibitors. Br. J. Psychiatry. 1985 ; 146 : 576-584.

· Parry, B.L. Reproductive factors affecting the course of affective illness in women. Psychiatr. Clin. North Am. 1989 ; 12 : 207-220.

· Pastuszak, A., Schik-Boschetto, B., Zuber, C. et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA. 1993 ; 269 : 2246-2248.

· Pentel, P. & Peterson, C.D. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann. Emerg. Med. 1986 ; 9 : 1349-1352.

· Perucca, E., Gatti, G., Cipolla, G. et al. Inhibition of diazepam metabolism by fluovoxamine : a pharmacokinetic study in normal volunteers. Clin. Pharmacol. Ther. 1994 ; 56 : 471-476.

· Physicians' Desk Reference. 50th ed. Montvale, NJ : Medical Economics, 1996.

· Pletscher, A. The discovery of antidepressants : a winding path. Experientia 1991 47: 4-8.

· Preskorn, S.H., Alderman, J., Chung, M. et al. Pharmacokinetics of desipramine coadministered with sertraline and fluoxetine. J. Clin. Psychopharmacol. 1994 ; 14 : 90-98.

· Puig-Antich, J., Perel, J.M., Lupatkin, W. et al., Imipramine in prepuberal major depressive disorders. Arch. Gen. Psychiatry. 1987 ; 44 : 81-89.

Principio de página

R

· Rabkin, J.G., McGrath, P.J., Quitkin, F.M. et al. Effects of pill-giving on maintenance of placebo response in patients with chronic mild depression. Am. J. Psychiatry. 1990 ; 147 : 1622-1626.

· Read, A.E., Laidlaw, J. & McCarthy, C.F. Effects of chlorpromazine in patients with hepatic disease. Br. Med. J. 1969 ; 3 : 497.

· Reidenberg, M.M. & Lowenthal, D.T. Adverse nondrug reactions. N. Engl. J. Med. 1968 ; 279 : 678-679.

· Relling, M.V., Lin, J.S., Ayers, G.D. et al. Racial and gender differences in N-acetyl-transferase, xanthine oxidase and CYP1A2 activities. Clin. Pharmacol. Ther. 1992 ; 52 : 643-658.

· Richelson, E. Biological basis of depression and therapeutic relevance. J. Clin. Psychiatry. 1991 ; 52 (suppl. 6) : 4-10.

· Richelson, E. Pharmacokinetic drug interactions of new antidepressants : a review of the effects on the metabolism of other drugs. Mayo Clin. Proc. 1997 ; 72 : 835-847.

· Robinson, D.S. & Prien, R.F. Clinical study design. Critical issues. In Bloom, F.E. & Kupfer, D.J. Psychopharmacology : the fourth generation of progress. Raven Press. New York, 1995.

· Rosa, F. Spina bifida in infants of women treated with carbamazepine during pregnancy. N. Engl. J. Med. 1991 ; 324 : 674-677.

· Rosselli, H. Historia de la psiquiatría en Colombia. Edit. Horizontes, Bogotá. 1968.

Principio de página

S

· Sachdeo, R.C. & Belendiuk, G. Generic versus branded carbamazepine. Lancet. 1987 ; 1 : 1432.

· Schmider, J., Greenblatt, D.J., Von Moltke, L. & Shader, R.I. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions : implications for diazepam disposition in humans (editorial). J. Clin. Psychopharmacol. 1996 ; 16 : 267-.272.

· Schou, M., Goldfield, M.D., Weinstein, M.R. et al. Lithium and pregnancy. I. report from the Register of Lithium Babies. BMJ. 1973 ; 2 : 135-136.

· Schou, M. What happened to the lithium babies ? a follow-up study of children born without malformations. Acta Psychiatr. Scand. 1976 ; 54 : 193-197.

· Scolnik, D., Nulman, I., Rovet, J. et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA. 1994 ; 271 : 767-770.

· Shader, R.I., Greenblatt, D.J. & von Moltke, L.L. Fluoxetine inhibition of phenytoin metabolism. J. Clin. Psychopharmacol. 1994 ; 14 : 375-376.

· Shargel, L. & Andrew, B.C. Applied biopharmaceutics and phramacokinetics. Prentice-Hall International. Connecticut, 1993.

· Sindrup, S.H., Brosen, K., Gram, L.F. et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin. Pharmacol. Ther. 1992 ; 51 : 278-287.

· Smith, B. & Prockop. D.J. Central-nervous-system effects of ingestion of L-tryptophan by normal subjects. New Engl. J. Med. 1962 ; 267 : 1338-1341.

· Smith, R.B., Divoll, M., Gillespie, W.R. & Greenblatt, D.J. Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam. J. Clin. Psychopharmacol. 1983 ; 3 : 172-176.

· Snyder, S. & Yamamura, H. Antidepressants and the muscarinic acetylcholine receptor. Arch. Gen. Psychiatry. 1977 ; 2 : 236-239.

· St. Clair, S.M. & Schirmer, R.G. First-trimester exposure to alprazolam. Obstet. Gynecol. 1992 ; 80 : 843-846.

· Stanilla, J. & Simpson, G. Drugs to treat extrapyramidal side effects. In Schatzberg, A. & Nemeroff, C.B. (eds.) Textbook of psychopharmacology. American Psychiatric Press. Washington, 1995.

· Stowe, Z.N. & Nemeroff, C.B. Psychopharmacology during pregnancy and lactation. In Schatzberg, A. & Nemeroff, C.B. (eds.) Textbook of psychopharmacology. American Psychiatric Press. Washington, 1995.

· Swartzman, L.C. & Burkell, J. Expectations and the placebo effect in clinical drug trials : why we should not turn a blind eye to unblinding, and other cautionary notes. Clin. Pharmacol. Ther. 1998 ; 64 : 1-7.

Principio de página

T-U

· Thomson, R. Side effects and placebo amplification. Br. J. Psychiatry. 1982 ; 140 : 64-68.

· Thompson, C. Bringing the gap between psychiatric practice and primary care. Int. Clin. Psychopharm.: 1992;7/2.

· Thummel, K.E., O'Shea, D., Paine, M.F. et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 1996 ; 59 : 491-502.

· USP-DI, Drug Information for the Health Care Professional. 17th edition. Rockville, MD, United States Pharmacopeial Convention, Inc., 1997.

Principio de página

V

· Van Kammen, D.P. & Marder, S.R. Dopamine receptor antagonists. In Kaplan, H.I. & Sadock, B. Comprehensive Textbook of Psychiatry. 6th edn. W & W. Baltimore, 1995.

· Von Moltke, L., Greenblatt, D.J., Harmatz, J.S. et al. In vitro inhibition of desipramine (DMI) oxidation by fluoxetine (F) and norfluoxetine (NF) is greater than inhibition by sertraline (S) or desmethylsertraline (DS). Clin. Pharmacol. Ther. 1993 ; 53 : 198.

· Von Moltke, L.L., Greenblatt, D.J., Court, M.H. et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine : comparison with other selective serotonin reuptake inhibitor antidepressants. J. Clin. Psychopharmacol. 1995 ; 15 : 125-131.

· Von Moltke, L.L., Greenblatt, D.J., Duan, S.X. et al. In vitro biotransformation of phenacetin to acetaminophen. Clin. Pharmacol. Ther. 1996 ; 59 : 175.

· Vorhees, C.V., Brunner, R.L. & Butcher, R.E. Psychotropic drugs as behavioral teratogens. Science. 1979 ; 205 ; 1220-1225.

Principio de página

W-Y-Z

· Webster, P.A.C. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet. 1973 ; 2 : 318-319.

· Wegner, C. & Nau, H. Alteration of embryonic folate metabolism by valproic acid during organogenesis : implications for mechanism of teratogenesis. Neurology. 1992 ; 42 (suppl. 5) : 17-24.

· Weiner, M. & Weiner, G.J. The kinetics and dynamics of responses to placebo. Clin. Pharmacol. Ther. 1996 ; 60 : 247-254.

· Whitelaw, A.G.L., Cummings, A.J. & McFayden, I.R. Effect of maternal lorazepam on the neonate. BMJ. 1981 ; 282 : 1106-1108.

· Wisner, K.L., Perel, J.M. & Findling, R.L. Antidepressant treatment during brest-feeding. Am. J. Psychiatry. 1996 ; 153 : 1132-1137.

· Yonkers, K.A., Kando, J.C., Cole, J.O. & Blumenthal, S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am. J. Psychiatry. 1992 ; 149 : 587-595.

· Zhang, Y., Reviriego, J., Lou, Y.Q. et al. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenitoin : interethnic differences in comparison with white subjects. Clin. Pharmacol. Ther. 1990 ; 48 : 496-502.

· Ziegler, V.E. & Biggs, J.T. Tricyclic plasma levels: effect of age, race, sex and smoking. JAMA. 1977 ; 238 : 2167-2169.

Principio de página

Comentarios Principio de página